Medtronic PLC
MDT Healthcare Medical Devices
Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025. In the quarter to July 2026, revenue grew 13.7%, EPS grew 42.0%, free cash flow grew 120.9% and total debt fell 1.59%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for three, operating cash flow growth for three.
Follow MDT
Medtronic PLC (MDT) EPS (diluted)
Medtronic PLC's EPS (diluted) for fiscal 2026 was $3.73, unchanged from fiscal 2025. Over the twelve months to 31 July 2026 it was $4.06. Over the past ten years it has ranged from $2.27 (fiscal 2018) to $3.73 (fiscal 2026) — the current reading is the highest in ten years. Medtronic PLC ranks 14th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | $3.73 | 3.32% |
| FY2025 | $3.61 | 30.80% |
| FY2024 | $2.76 | (2.13%) |
| FY2023 | $2.82 | (24.40%) |
| FY2022 | $3.73 | 40.23% |
| FY2021 | $2.66 | (24.86%) |
| FY2020 | $3.54 | 3.81% |
| FY2019 | $3.41 | 50.22% |
| FY2018 | $2.27 | (21.45%) |
| FY2017 | $2.89 | 16.53% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jul 2026 | $1.14 | 18.75% |
| Apr 2026 | $0.96 | 7.87% |
| Jan 2026 | $0.89 | (16.82%) |
| Oct 2025 | $1.07 | 32.10% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SYK Stryker Corporation compare | $9.65 |
| STE STERIS plc compare | $8.18 |
| GEHC GE HealthCare Technologies Inc. compare | $4.36 |
| MDT Medtronic PLC | $4.06 |
| ABT Abbott Laboratories compare | $3.09 |
| DXCM DexCom, Inc. compare | $2.53 |
| BSX Boston Scientific Corporation compare | $2.47 |
| EW Edwards Lifesciences Corporation compare | $1.74 |
| PHG Koninklijke Philips N.V. compare | $1.36 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on MDT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement